Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.

Significant reduction also seen in change from baseline in daily OFF times vs placebo. HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily ...

At close: April 11 at 4:00:01 p.m. EDT ...